Drugs / PYC-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06461286 | Oct 2024 → Aug 2026 overdue | OPA1-related optic atrophy with or without extraocular features, autosomal dominant optic atrophy, classic form | PYC Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06970106 | Sep 2025 → Oct 2029 expected | OPA1-related optic atrophy with or without extraocular features, autosomal dominant optic atrophy | PYC Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PYC-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06970106 ↗ |
| Modality | Oligonucleotide (other) | “peptide-phosphorodiamidate morpholino oligonucleotide” NCT06970106 ↗ |
| Route | Intravitreal | “Each eligible participant will receive a single intravitreal (IVT) injection of PYC-001 in their study eye on Day 1” NCT06461286 ↗ |